FONT-SIZE Plus   Neg

Teva Wins FDA Approval For Qnasl Nasal Aerosol To Treat Allergic Rhinitis


Generic drugmaker Teva Pharmaceutical Industries Ltd. (TEVA) on Monday said the U.S. Food and Drug Administration has approved Qnasl Nasal Aerosol, a new, dry nasal aerosol corticosteroid that treats seasonal nasal and year-round nasal allergy symptoms in adults and adolescents who are 12 years old or above.

The approval was based on a comprehensive clinical development program that assessed the product's safety and efficacy in the treatment of seasonal allergic rhinitis and perennial allergic rhinitis in patients 12 years of age and older.

Allergic rhinitis is the most common allergic disease in the U.S. It affects more than one in five people, causing some to have symptoms year round and others to experience symptoms during specific times of the year.

The safety and efficacy of Qnasl Nasal Aerosol was demonstrated in four, Phase III trials, where patients received Qnasl 320 mcg once-daily administered as two sprays in each nostril.

Intra-nasal corticosteroids are recommended as first-line therapy for allergic rhinitis and the only available option on the market before the approval of Qnasl (beclomethasone dipropionate) were aqueous formulations.

The product is expected to be available by prescription in April. It will be the first marketed non-aqueous or dry nasal aerosol in a product category that reports annual sales of $2.5 billion.

Qnasl is delivered as a once-daily, pressurized, hydrofluoroalkane or HFA-propelled non-aqueous aerosol that is environmentally friendly and offers a built-in dose counter.

Gary Gross, practicing allergist and co-founder of the Dallas Asthma and Allergy Center, said, "There are some patients with allergic rhinitis who report dissatisfaction with the currently available therapies. The approval of QNASL offers these patients a safe and effective treatment option with a new dry mode of delivery."

Teva shares, which closed at $43.07 on Friday, are adding 2.1 percent in pre-market activity.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Chipmaker Qualcomm is reportedly in talks with NXP Semiconductor NV (NXPI) for a possible acquisition, reports said. According to Bloomberg, negotiations are on with a probable price of $110 t $120 per NXP share. The deal would value NXP at around $34.7 billion. Regulators have confirmed the eleventh U.S. fatality linked to Takata Corp.'s defective air bag inflators. The National Highway Traffic Safety Administration or NHTSA said Thursday that a crash fatality in Riverside County, California, was tied to the rupture of a recalled Takata air bag inflator. Reynolds American Inc. (RAI) on Friday confirmed that British American Tobacco plc (BATS.L, BTI) has offered to buy the remaining 57.8 percent stake that it does not own in the US tobacco company for $47 billion. Reynolds said its board of directors will evaluate the offer, and respond accordingly to BAT, which currently owns 42.2 percent stake in Reynolds. The proposal represents an enterprise va
comments powered by Disqus
Follow RTT